Cationorm

DEVICE2 trials

Sponsors

TRB Chemedica, VISUfarma SpA

Conditions

Dry EyeEvaporative Dry Eye Disease

Unknown Phase

REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye

TerminatedNCT03460548

TRB ChemedicaDry Eye

Start: 2018-03-30End: 2019-06-12Updated: 2020-04-20

Evaluation of MAF-1217 in Patients With DED

CompletedNCT03833882

VISUfarma SpAEvaporative Dry Eye Disease

Start: 2018-11-27End: 2019-06-19Updated: 2019-07-15

Related Papers

<p>Efficacy and Safety of VisuEvo® and Cationorm® for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial</p>

Clinical ophthalmology2020-06-0122 citations